Novocure
Ashley Cordova, 212 767 7558
acordova@novocure.com
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal of Radiation Oncology • Biology • Physics, also known as the Red Journal. The study results suggest that customizing transducer array layouts based on tumor locations can significantly increase field strength within tumors.
The anti-mitotic effect of TTFields is dose-dependent starting at an electric field strength of 1 V/cm and increasing with increasing field intensity. Consistent with prior research, the average electric field induced in the published model exceeded the therapeutic threshold of 1 V/cm in all tumors. Field strength within a tumor did not correlate with its size or shape but was dependent on tumor location. Field strength always increased when the array layout was adapted according to the anatomic location of the tumor.
The full study can be accessed here.
Novocure offers a transducer array layout system, the NovoTAL System, allowing certified Optune prescribers to optimize TTFields therapy for each glioblastoma, or GBM, patient. The personalized transducer array layout maximizes the intensity of TTFields within a patient’s tumor based on morphological measurements of the head, tumor size and location. With the NovoTAL system, healthcare providers who have been trained and certified can generate transducer array layout maps for their Optune patients as an office-based procedure.
About Tumor Treating Fields Therapy
Tumor Treating Fields
(TTFields) therapy is delivered by a portable, non-invasive medical
device designed for continuous use by patients. In vitro and in
vivo studies have shown that TTFields therapy slows and reverses
tumor growth by inhibiting mitosis, the process by which cells divide
and replicate. TTFields therapy creates low intensity, alternating
electric fields within a tumor that exert physical forces on
electrically charged cellular components, preventing the normal mitotic
process and causing cancer cell death.
Approved Indications
In the United States, Optune is
intended as a treatment for adult patients (22 years of age or older)
with histologically-confirmed glioblastoma multiforme (GBM).
In the United States, Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.
In the United States, for the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
In the European Union, Optune is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant temozolomide, concomitant to maintenance temozolomide. The treatment is intended for adult patients, 18 years of age or older, and should be started more than four weeks after surgery and radiation therapy with adjuvant temozolomide. Treatment may be given together with maintenance temozolomide and after maintenance temozolomide is stopped.
In the European Union, Optune is also intended for the treatment of patients with recurrent GBM who have progressed after surgery, radiotherapy and temozolomide treatment for their primary disease. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after the latest surgery, radiation therapy or chemotherapy.
Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301 in the US or by email at supportEMEA@novocure.com in the European Union.
About Novocure
Novocure is a Jersey Isle oncology company
pioneering a novel therapy for solid tumors called TTFields. Novocure’s
U.S. operations are based in Portsmouth, New Hampshire, and New York
City. Additionally, the company has offices in Germany, Switzerland, and
Japan and a research center in Haifa, Israel. For additional information
about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts
or statements of current condition, this press release may contain
forward-looking statements. Forward-looking statements provide
Novocure’s current expectations or forecasts of future events. These may
include statements regarding anticipated scientific progress on its
research programs, development of potential products, interpretation of
clinical results, prospects for regulatory approval, manufacturing
development and capabilities, market prospects for its products, and
other statements regarding matters that are not historical facts. You
may identify some of these forward-looking statements by the use of
words in the statements such as "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe" or other words and terms of
similar meaning. Novocure's performance and financial results could
differ materially from those reflected in these forward-looking
statements due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K filed
on March 1, 2016, with the U.S. Securities and Exchange Commission.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not rely on
any such factors or forward-looking statements. Furthermore, Novocure
does not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak only as
of the date hereof. The Private Securities Litigation Reform Act of 1995
permits this discussion.
